We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

151 hedge funds and large institutions have $192M invested in Heron Therapeutics in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,289% more call options, than puts

Call options by funds: $2.19M | Put options by funds: $158K

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

57% more capital invested

Capital invested by funds: $122M → $192M (+$70M)

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

7% more funds holding

Funds holding: 141 → 151 (+10)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8.86% less ownership

Funds ownership: 84.11% → 75.24% (-8.9%)

Holders
151
Holders Change
+10
Holders Change %
+7.09%
% of All Funds
2.2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
30
Increased
45
Reduced
38
Closed
18
Calls
$2.19M
Puts
$158K
Net Calls
+$2.04M
Net Calls Change
+$669K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$5.64M
2
TC
Tejara Capital
United Kingdom
+$3.49M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.75M
4
MAM
Monaco Asset Management
Monaco
+$1.68M
5
CPC
Congress Park Capital
New York
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$8.38M
2
JP Morgan Chase
JP Morgan Chase
New York
-$7.42M
3
GPP
Great Point Partners
Connecticut
-$4.88M
4
DTC
Deep Track Capital
Connecticut
-$2.15M
5
BlackRock
BlackRock
New York
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
126
PNC Financial Services Group
Pennsylvania
$2.75K -$100 -91 -5%
CFGS
127
Concourse Financial Group Securities
Alabama
$2.69K – – –
ASN
128
Advisory Services Network
Georgia
$2.51K +$1.63K +1,479 New
RCM
129
Raleigh Capital Management
North Carolina
$2.47K +$1.6K +1,453 New
AWM
130
Avior Wealth Management
Nebraska
$2.22K +$1.44K +1,307 New
BCV
131
Banque Cantonale Vaudoise
Switzerland
$2K – – –
SPIA
132
Steward Partners Investment Advisory
New York
$1.7K – – –
WAS
133
Winch Advisory Services
Wisconsin
$1.7K – – –
BEI
134
Benjamin Edwards Inc
Missouri
$1K -$791 -718 -47%
CB
135
CNB Bank
Pennsylvania
$850 – – –
NECFA
136
New England Capital Financial Advisors
Connecticut
$808 – – –
OP
137
ORG Partners
Indiana
$680 +$440 +400 New
HNB
138
Huntington National Bank
Ohio
$629 – – –
WTA
139
Washington Trust Advisors
Massachusetts
$624 – – –
Comerica Bank
140
Comerica Bank
Texas
$600 -$156 -142 -29%
AF
141
Allworth Financial
California
$512 +$331 +301 New
FFO
142
Fortitude Family Office
Arizona
$478 +$309 +281 New
PA
143
Parallel Advisors
California
$340 – – –
EBA
144
Eagle Bay Advisors
New York
$328 – – –
National Bank of Canada
145
National Bank of Canada
Quebec, Canada
$188 -$551 -500 -83%
AF
146
Advisornet Financial
Minnesota
$187 – – –
Nisa Investment Advisors
147
Nisa Investment Advisors
Missouri
$170 -$1.08K -985 -91%
EWM
148
Evermay Wealth Management
Virginia
$170 – – –
GPFA
149
Game Plan Financial Advisors
Ohio
$170 +$110 +100 New
GWSG
150
GPS Wealth Strategies Group
Colorado
$122 – – –
3 4 5
6
7

HRTX Hedge Fund Activity: Q4 2023 in Review

151 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2023, worth a combined $192M — up 57% from $122M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HRTX positions and 18 closed out — a net gain of 12 holders — while 45 added to existing stakes and 38 trimmed.

The largest buyer was OrbiMed, adding an estimated $5.64M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $8.38M sold.

  • 151 institutional investors held Heron Therapeutics (HRTX) as of Q4 2023, up from 141 in Q3 2023.
  • Funds reported $192M of Heron Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
  • 30 funds opened new Heron Therapeutics positions in Q4 2023 and 18 closed out, a net change of +12 holders.
  • The largest Heron Therapeutics buyer in Q4 2023 was OrbiMed, an estimated $5.64M added.
  • The largest Heron Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $8.38M sold.

Based on aggregated 13F filings for Q4 2023.